SCHEMBL20985264

SCHEMBL20985264

Nc1cc(COC2CCCCO2)ccc1N[C@H]1CC[C@@H](C(=O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.41
CREBBP Q92793 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ICAM1 P05362 1/20 0.39
SELE P16581 1/20 0.39
EP300 Q09472 1/20 0.38
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
CA12 O43570 5/20 0.34
CA1 P00915 5/20 0.34
CA2 P00918 5/20 0.34
CA9 Q16790 5/20 0.34
CHEK1 O14757 1/20 0.34
NTRK1 P04629 1/20 0.34
MET P08581 1/20 0.34
PIM1 P11309 1/20 0.34
LTK P29376 1/20 0.34
GRK5 P34947 1/20 0.34
MAP2K2 P36507 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20985266 1.00 ALOX15 (0.41) ALOX15CREBBPMEN1KMT2AICAM1
SCHEMBL29937897 0.88 ALOX15 (0.48) ALOX15CREBBPMEN1KMT2AICAM1
SCHEMBL21025634 0.88 ALOX15 (0.48) ALOX15CREBBPMEN1KMT2AICAM1
SCHEMBL21025909 0.88 ALOX15 (0.48) ALOX15CREBBPMEN1KMT2AICAM1
SCHEMBL20985427 0.85 HCAR3 (0.49) MEN1KMT2AALDH1A1HCAR3
SCHEMBL20985428 0.85 HCAR3 (0.49) MEN1KMT2AALDH1A1HCAR3
SCHEMBL16634584 0.78 CREBBP (0.49) CREBBPMEN1KMT2AICAM1SELE
SCHEMBL16634747 0.77 CREBBP (0.46) CREBBPMEN1KMT2AICAM1SELE
SCHEMBL16645316 0.74 CREBBP (0.44) ALOX15CREBBPMEN1KMT2AICAM1
SCHEMBL29313601 0.74 MAPT (0.45) CREBBPMEN1KMT2AALDH1A1HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2021-07-20 US disclosed
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2019-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190151295-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES IRAK1, IRAK4, IRAK2 ALOX15 4415/4885CREBBP 1226/4885MEN1 2454/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 ALOX15 4514/4885CREBBP 978/4885MEN1 2168/4885
US-11065231-B2 Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 ALOX15 4415/4885CREBBP 1226/4885MEN1 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.